An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3- FKHR oncogene

Molecular and Cellular Biology

Volumn 20, Issue 14, 2000, Pages 5019-5031

  Fredericks, William J ^a   Ayyanathan, Kasirajan ^a   Herlyn, Meenhard ^a   Friedman, Josh R ^a,b   Rauscher III, Frank J ^a  

^a WISTAR INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CHROMOSOME TRANSLOCATION; COMPETITIVE INHIBITION; EFFECTOR CELL; GENE TARGETING; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPORTER GENE; RHABDOMYOSARCOMA; SARCOMA CELL; TRANSCRIPTION REGULATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CARCINOGENICITY TESTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; RHABDOMYOSARCOMA, ALVEOLAR; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0033917420     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.14.5019-5031.2000     Document Type: Article

References (76)

1. Amthor, H., B. Christ, and K. Patel. 1999. A molecular mechanism enabling continuous embryonic muscle growth - a balance between proliferation and differentiation. Development 126:1041-1053.
2. Anderson, J., A. Gordon, K. Pritchard-Jones, and J. Shipley. 1999. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 26: 275-285.
3. Ayala, J. E., R. S. Streeper, J. S. Desgrosellier, S. K. Durham, A. Suwanichkul, C. A. Svitek, J. K. Goldman, F. G. Barr, D. R. Powell, and R. M. O'Brien. 1999. Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. Diabetes 48:1885-1889.
4. Barr, F. G. 1999. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma. Cancer Res. 59:1711s-1715s.
5. Beerli, R. R., D. J. Segal, B. Dreier, and C. F. Barbas III. 1998. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl. Acad. Sci. USA 95:14628-14633.
6. Bendall, A. J., J. Ding, G. Hu, M. M. Shen, and C. Abate-Shen. 1999. Msx1 antagonizes the myogenic activity of Pax3 in migrating limb muscle precursors. Development 126:4965-4976.
7. Bennicelli, J. L., S. Advani, B. W. Schafer, and F. G. Barr. 1999. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Oncogene 18:4348-4356.
8. Bennicelli, J. L., W. J. Fredericks, R. B. Wilson, F. J. Rauscher III, and F. G. Barr. 1995. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-130.
9. Bernasconi, M., A. Remppis, W. J. Fredericks, F. J. Rauscher III, and B. W. Schafer. 1996. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl. Acad. Sci. USA 93:13164-13169.
10. Borycki, A. G., J. Li, F. Jin, C. P. Emerson, and J. A. Epstein. 1999. Pax3 functions in cell survival and in pax7 regulation. Development 126:1665-1674.
11. Brand-Saberi, B., and B. Christ. 1999. Genetic and epigenetic control of muscle development in vertebrates. Cell Tissue Res. 296:199-212.
12. Chalepakis, G., M. Goulding, A. Read, T. Strachan, and P. Gruss. 1994. Molecular basis of splotch and Waardenburg Pax-3 mutations. Proc. Natl. Acad. Sci. USA 91:3685-3689.
13. Chalepakis, G., F. S. Jones, G. M. Edelman, and P. Grass. 1994. Pax-3 contains domains for transcription activation and transcription inhibition. Proc. Natl. Acad. Sci. USA 91:12745-12749.
14. Chalepakis, G., J. Wijnholds, and P. Gruss. 1994. Pax-3-DNA interaction: flexibility in the DNA binding and induction of DNA conformational changes by paired domains. Nucleic Acids Res. 22:3131-3137.
15. Cobaleda, C., J. Perez-Losada, and I. Sanchez-Garcia. 1998. Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms. Bioessays 20:922-930.
16. Czerny, T., G. Schaffner, and M. Busslinger. 1993. DNA sequence recognition by Pax proteins: bipartite structure of the paired domain and its binding site. Genes Dev. 7:2048-2061.
17. Dahl, E., H. Koseki, and R. Balling. 1997. Pax genes and organogenesis. Bioessays 19:755-765.
18. Daston, G., E. Lamar, M. Olivier, and M. Goulding. 1996. Pax-3 is necessary for migration but not differentiation of limb muscle precursors in the mouse. Development 122:1017-1027.
19. Datta, S. R., A. Brunet, and M. E. Greenberg. 1999. Cellular survival: a play in three Akts. Genes Dev. 13:2905-2927.
20. Davis, R. J., C. M. D'Cruz, M. A. Lovell, J. A. Biegel, and F. G. Barr. 1994. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54:2869-2872.
21. Dickman, E. D., R. Rogers, and S. J. Conway. 1999 Abnormal skeletogenesis occurs coincident with increased apoptosis in the Splotch (Sp2H) mutant: putative roles for Pax3 and PDGFRalpha in rib patterning. Anat. Rec. 255:353-361.
22. Dietrich, S. 1999. Regulation of hypaxial muscle development. Cell Tissue Res. 296:175-182.
23. Dietrich, S., F. Abou-Rebyeh, H. Brohmann, F. Bladt, E. Sonnenberg-Riethmacher, T. Yamaai. A. Lumsden, B. Brand-Saberi, and C. Birchmeier. 1999. The role of SF/HGF and c-Met in the development of skeletal muscle. Development 126:1621-1629.
24. Douglass, E. C., M. Valentine, E. Etcubanas, D. Parham, B. L. Webber, P. J. Houghton, J. A. Houghton, and A. A. Green. 1987. A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet. Cell Genet. 45:148-155. (Erratum, 47:232, 1988.)
25. Durham, S. K., A. Suwanichkul, A. O. Scheimann, D. Yee, J. G. Jackson, F. G. Barr, and D. R. Powell. 1999. FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 140:3140-3146.
26. El-Badry, O. M., C. Minniti, E. C. Kohn, P. J. Houghton, W. H. Daughaday, and L. J. Helman. 1990. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1:325-331.
27. Epstein, J. A., D. N. Shapiro, J. Cheng, P. Y. Lam, and R. L. Maas. 1996 Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc. Natl. Acad. Sci. USA 93:4213-4218.
28. Epstein, J. A., B. Song, M. Lakkis, and C. Wang. 1998. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol. Cell. Biol. 18:4118-4130.
29. Ferracini, R., M. Olivero, M. F. Di Renzo, M. Martano, C. De Giovanni, P. Nanni, G. Basso, K. Scotlandi, P. L. Lollini, and P. M. Contoglio. 1996. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12:1697-1705.
30. Ferry, R. J., Jr., L. E. Katz, A. Grimberg, P. Cohen, and S. A. Weinzimer. 1999. Cellular actions of insulin-like growth factor binding proteins. Horm. Metab. Res. 31:192-202.
31. Fredericks, W. J., N. Galili, S. Mukhopadhyay, G. Rovera, J. Bennicelli, F. G. Barr, and F. J. Rauscher III. 1995. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15:1522-1535.
32. Friedman, J. R., W. J. Fredericks, D. E. Jemen, D. W. Speicher, X. P. Huang, E. G. Neilson, and F. J. Rauscher III. 1996. KAP-1, a novel co-repressor for the highly-conserved KRAB repression domain. Genes Dev. 10:2067-2078.
33. Fukazawa, H., S. Mizuno, and Y. Uehara. 1995. A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal. Biochem. 228:83-90.
34. Galibert, M. D., U. Yavuzer, T. J. Dexter, and C. R. Goding. 1999. Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter. J. Biol. Chem. 274:26894-26900.
35. Galili, N., R. J. Davis, W. J. Fredericks, S. Mukhopadhyay, F. J. Rauscher III, B. S. Emanuel, G. Rovera, and F. G. Barr. 1993. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat. Genet. 5:230-235.
36. Genini, M., P. Schwalbe, F. A. Scholl, and B. W. Schafer. 1996. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int. J. Cancer 66:571-577.
37. Ginsberg, J. P., R. J. Davis, J. L. Bennicelli, L. E. Nauta, and F. G. Barr. 1998. Upregulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 58:3542-3546.
38. Goulding, M. D., G. Chalepakis, U. Deutsch, J. R. Erselius, and P. Gruss. 1991. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J. 10:1135-1147.
39. Hill, A. L., S. A. Phelan, and M. R. Loeken. 1998. Reduced expression of pax-3 is associated with overexpression of cdc46 in the mouse embryo. Dev. Genes Evol. 208:128-134.
40. Hollenbach, A. D., J. E. Sublett, C. J. McPherson, and G. Grosveld. 1999. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx. EMBO J. 18:3702-3711.
41. Inukai, T., T. Inaba, T. Yoshihara, and A. T. Look. 1997. Cell transformation mediated by homodimeric E2A-HLF transcription factors. Mol. Cell. Biol. 17:1417-1424.
42. Inukai, T., A. Inoue, H. Kurosawa, K. Goi, T. Shinjyo, K. Ozawa, M. Mao, T. Inaba, and A. T. Look. 1999. SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol. Cell 4:343-352.
43. Khan, J., M. L. Bittner, L. H. Saal, U. Teichmann, D. O. Azorsa, G. C. Gooden, W. J. Pavan, J. M. Trent, and P. S. Meltzer. 1999. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. USA 96:13264-13269.
44. Khan, J., R. Simon, M. Bittner, Y. Chen, S. B. Leighton, T. Pohida, P. D. Smith, Y. Jiang, G. C. Gooden, J. M. Trent, and P. S. Meltzer. 1998. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res. 58:5009-5013.
45. Kouraklis, G., T. J. Triche, R. Wesley, and M. Tsokos. 1999. Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines. Pediatr. Res. 45:552-558.
46. Luckow, B., and G. Schutz. 1987. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res. 15:5490.
47. Ma, Z. Q., M. J. Tsai, and S. Y. Tsai. 1999. Suppression of gene expression by tethering KRAB domain to promoter of ER target genes. J. Steroid Biochem. Mol. Biol. 69:155-163.
48. Magnaghi, P., C. Roberts, S. Lorain, M. Lipinski, and P. J. Scambler. 1998. HIRA, a mammalian homologue of Saccharomyces cerevisiae transcriptional co-repressors, interacts with Pax3. Nat. Genet. 20:74-77.
49. Mansouri, A., G. Goudreau, and P. Gruss. 1999. Pax genes and their role in organogenesis. Cancer Res. 59:1707s-1710.
50. Mansouri, A., and P. Gruss. 1998. Pax3 and Pax7 are expressed in commissural neurons and restrict ventral neuronal identity in the spinal cord. Mech. Dev. 78:171-178.
51. Margolin, J. F., J. R. Friedman, W. K. Meyer, H. Vissing, H. J. Thiesen, and F. J. Rauscher III. 1994. Kruppel-associated boxes are potent transcriptional repression domains. Proc. Natl. Acad. Sci. USA 91:4509-4513.
52. Maroto, M., R. Reshef, A. E. Munsterberg, S. Koester, M. Goulding, and A. B. Lassar. 1997. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89:139-148.
53. May, W. A., S. L. Lessnick, B. S. Braun, M. Klemsz, B. C. Lewis, L. B. Lunsford, R. Hromas, and C. T. Denny. 1993. The Ewing's sarcoma EWS/ FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13:7393-7398.
54. Mennerich, D., K. Schafer, and T. Braun. 1998. Pax-3 is necessary but not sufficient for 1bx1 expression in myogenic precursor cells of the limb. Mech. Dev. 73:147-158.
55. Merlino, G., and L. J. Helman. 1999. Rhabdomyosarcoma - working out the pathways. Oncogene 18:5340-5348.
56. Minniti, C. P., D. Luan, C. O'Grady, R. G. Rosenfeld, Y. Oh, and L. J. Helman. 1995. Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ. 6:263-269.
57. Mosmann, T. 1983. Rapid colorimetric assay far cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
58. Mu, Z. M., X. F. Le, A. B. Glassman, and K. S. Chang. 1996. The biologic function of PML and its role in acute promyelocytic leukemia. Leuk. Lymphoma 23:277-285.
59. Peng, H., G. E. Begg, D. C. Schultz, J. R. Friedman, D. E. Jensen, D. W. Speicher, and F. J. Rauscher III. 2000. Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions. J. Mol. Biol. 295:1139-1162.
60. Peso, L., V. M. Gonzalez, R. Hernandez, F. G. Barr, and G. Nunez. 1999. Regulation of the forkhead transcription factor FKHR, but not the PAX3-FKHR fusion protein, by the serine/threonine kinase Akt. Oncogene 18: 7328-7333.
61. Phelan, S. A., M. Ito, and M. R. Loeken. 1997. Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis. Diabetes 46:1189-1197.
62. Phelan, S. A., and M. R. Loeken. 1998. Identification of a new binding motif for the paired domain of Pax-3 and unusual characteristics of spacing of bipartite recognition elements on binding and transcription activation. J. Biol. Chem. 273:19153-19159.
63. Rauscher, F. J., III, and P. Vogt (ed.). 1997. Chromosomal translocations and oncogenic transcription factors, vol. 220. Springer-Verlag, Berlin, Germany.
64. Ryan, R. F., D. C. Schultz, K. Ayyanathan, P. B. Singh, J. R. Friedman, W. J. Fredericks, and F. J. Rauscher III. 1999. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Mol. Cell. Biol. 19:4366-4378.
65. Sanchez-Garcia, I. 1997. Consequences of chromosomal abnormalities in tumor development. Annu. Rev. Genet. 31:429-453.
66. Schafer, B. W., T. Czerny, M. Bernasconi, M. Genini, and M. Busslinger. 1994. Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. Nucleic Acids Res. 22:4574-4582.
67. Schafer, K., and T. Braun. 1999. Early specification of limb muscle precursor cells by the homeobox gene Lbx1h. Nat. Genet. 23:213-216.
68. Scheidler, S., W. J. Fredericks, F. J. Rauscher III, F. G. Barr, and P. K. Vogt. 1996. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc. Natl. Acad. Sci. USA 93:9805-9809.
69. Shapiro, D. N., B. G. Jones, L. H. Shapiro, P. Dias, and P. J. Houghton. 1994. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Investig. 94:1235-1242.
70. Tajbakhsh, S., D. Rocancourt, G. Cossu, and M. Buckingham. 1997. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89:127-138.
71. Tanaka, T., K. Mitani, M. Kurokawa, S. Ogawa, K. Tanaka, J. Nishida, Y. Yazaki, Y. Shibata, and H. Hirai. 1995. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol. Cell. Biol. 15:2383-2392.
72. Tassabehji, M., V. E. Newton, K. Leverton, K. Turnbull, E. Seemanova, J. Kunze, K. Sperling, T. Strachan, and A. P. Read. 1994. PAX3 gene structure and mutations: close analogies between Waardenburg syndrome and the Splotch mouse. Hum. Mol. Genet. 3:1069-1074.
73. Wang, W., P. Kumar, J. Epstein, L. Helman, J. V. Moore, and S. Kumar. 1998. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res. 58:4426-4433.
74. Watanabe, A., K. Takeda, B. Ploplis, and M. Tachibana. 1998. Epistatic relationship between Waardenburg syndrome genes MITF and PAX3. Nat. Genet. 18:283-286.
75. Wiggan, O., A. Tanigucbi-Sidle, and P. A. Hamel. 1998. Interaction of the pRB-family proteins with factors containing paired-like homeodomains. Oncogene 16:227-236.
76. Wilson, D., G. Sheng, T. Lecuit, N. Dostatni, and C. Desplan. 1993. Cooperative dimerization of paired class homeo domains on DNA. Genes Dev. 7:2120-2134.